Pulmonary Hypertension

A Deep Dive Into Pulmonary Hypertension - MedPage Today A Deep Dive Into Pulmonary Hypertension - MedPage Today Posted: 26 Mar 2019 12:00 AM PDT In this episode, Andrew Perry, MD, discusses pulmonary hypertension with Murali Chakinala, MD, who specializes in pulmonary vascular diseases at Washington University School of Medicine in St. Louis. During the course of the conversation, they cover the diagnosis and disease groupings related to this condition, as well as the available treatments. A transcript of the podcast follows: Perry: Maybe first let's start with you maybe saying your name and your title, and then I'll describe that case that I encountered. Chakinala: I'm Murali Chakinala. I'm a member of the pulmonary division at Washington University. I'm a Professor of Medicine, and I direct our Pulmonary Hypertension Care Center. Perry: Thank you for meeting with me today. This is actually a few months a...

Acceleron and Fulcrum Strike Deal to Address Pulmonary Diseases - BioSpace Acceleron and Fulcrum Strike Deal to Address Pulmonary Diseases - BioSpace Posted: 31 Dec 2019 07:20 AM PST Acceleron Pharma and Fulcrum Therapeutics are entering 2020 as partners to tackle pulmonary diseases. On Monday, the two companies forged a collaboration and license agreement that has the potential to be worth more than $450 million. The Cambridge, Mass.-based companies inked a deal to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. Fulcrum has a product engine and target identification platform that uses computational biology, as well as a proprietary relational database that will help in the identification of small molecules that control the expression of certain genes. Acceleron will use Fulcrum's platform to focus on genes that are known to impact specific pat...

PAH Can Be Identified in SSc Patients Using Exercise Testing, Study Says - Pulmonary Hypertension News PAH Can Be Identified in SSc Patients Using Exercise Testing, Study Says - Pulmonary Hypertension News Posted: 02 Dec 2019 12:00 AM PST Cardiopulmonary exercise testing can improve the ability of an algorithm to identify systemic sclerosis patients who have pulmonary arterial hypertension (PAH), a new study suggests. The study, " Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis ," was published in the journal Rheumatology . Systemic sclerosis (SSc) is one of the main conditions that predisposes a person to develop PAH. Identifying people with SSc-associated PAH as early as possible is important, because early diagnosis and starting treatment rapidly are predictors of good clinical outcomes in this patient popu...

Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor Cardiac MRI Could Be Useful in Pulmonary Arterial Hypertension Risk Stratification - Pulmonology Advisor Deciding to Start a New Medication Can Be Overwhelming - Pulmonary Hypertension News Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor Posted: 05 Dec 2019 12:00 AM PST A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension (PAH) who received dual endothelin receptor antagonist (ERA)/phosphodiesterase type 5 inhibitor (PDE5i) therapy. The opinions were published in CHEST . Researchers used MEDLINE to perform a sys...

Antiarrhythmic drug identified as potential treatment for pulmonary arterial hypertension - Medical Xpress Antiarrhythmic drug identified as potential treatment for pulmonary arterial hypertension - Medical Xpress Posted: 12 Dec 2019 12:00 AM PST Image demonstrates pulmonary arteries (PAs) and lung tissue from control, pulmonary arterial hypertension (PAH), and PAH and dofetilide treated rats. W indicates wall and L indicates lumen. Scale bars = 50 μm. Treatment with dofetilide inhibits pulmonary vascular remodeling associated with PAH, including wall thickening and lumen occlusion. . Credit: Shults, N.V., Rybka, V., Suzuki, Y.J., and Brelidze, T.I. High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs. A new study in The American Journal of Pathology sheds light on the pathology underlying PAH and shows that dofetilide, an FDA-...